Inclusion Criteria:

- Histologically/cytologically documented SCCHN, excluding salivary gland primary sites

- 18 years of age or older

- Have evaluable locoregional and/or metastatic disease according to RECIST that is not
appropriate for treatment by primary surgical resection or radiotherapy

- Have locoregional and/or metastatic disease that has failed to respond to or relapsed
from at least one prior chemotherapy or chemoradiotherapy

- Life expectancy of at least 4 months

- ECOG performance status of 0-2

- Use of effective means of contraception in patients of child-bearing potential

Exclusion Criteria:

- Other malignancy within 5 years except non-melanomatous skin cancer, or carcinoma in
situ of the cervix, bladder or head and neck

- Concurrent anticancer therapy other than that of this study

- Treatment with any anticancer drug within 28 days of day 1

- Radiotherapy within 28 days of day 1

- Any unresolved toxicity greater than NCI-CTCAE v 3.0 grade 2 from prior systemic
anticancer therapy

- Any prior therapy that targets the ErbB and/or VEGF pathways

- Concurrent therapy with any NSAID

- Known hypersensitivity characterized by acute bronchospasm, urticaria and/or rhinitis
to NSAIDs, including aspirin

- Serum creatinine > 1.5 x ULN

- Abnormal LFTs as outlined in protocol

- Blood pressure > 150/100mmHg

- Active unstable angina, or myocardial infarction within 6 months

- NYHA Grade II or greater congestive heart failure

- History of stroke within 6 months

- Clinically significant active peripheral vascular disease

- Absolute neutrophil count < 1000/mm3 or platelets < 100,000/mm3

- Evidence of bleeding diathesis or coagulopathy.

- Tumor encasing the carotid artery, or other major vessel that in the opinion of the
investigators is at risk for tumor-related hemorrhage

- Presence of central nervous system or brain metastases

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 1, or anticipation of need for major surgical procedure during the
course of the study

- Minor surgical procedures such as fine needle aspiration or core biopsy within 5 days
prior to day 1

- Pregnant or lactating

- History of abdominal fistula or intra-abdominal abscess within 6 months

- History of gastrointestinal ulcer, perforation, or bleeding within 6 months

- Serious non-healing wound or ulcer or active uncontrolled infection

- Bone fracture within 28 days

- Active substance abuse, defined by substance abuse of alcohol, cocaine or intravenous
drug use within 6 months